Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Liver Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 27 articles:
HTML format
Text format



Single Articles


    March 2019
  1. LEVY S, Samuel D
    Prevention of decompensation in cirrhosis: a new youth for beta blockers.
    Lancet. 2019 Mar 22. pii: S0140-6736(19)30736.
    PubMed     Text format    


  2. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet. 2019 Mar 22. pii: S0140-6736(18)31875.
    PubMed     Text format     Abstract available


  3. JANUSZEWICZ W, Corrie P, Liu H, Chan J, et al
    A sinister black finding in the stomach.
    Lancet. 2019;393:1149.
    PubMed     Text format    


  4. CORNEC-LE GALL E, Alam A, Perrone RD
    Autosomal dominant polycystic kidney disease.
    Lancet. 2019;393:919-935.
    PubMed     Text format     Abstract available


    February 2019
  5. OVADIA C, Seed PT, Sklavounos A, Geenes V, et al
    Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.
    Lancet. 2019 Feb 14. pii: S0140-6736(18)31877.
    PubMed     Text format     Abstract available


  6. PALMER KR, Xiaohua L, Mol BW
    Management of intrahepatic cholestasis in pregnancy.
    Lancet. 2019 Feb 14. pii: S0140-6736(18)32323.
    PubMed     Text format    


    January 2019
  7. BRAILLON A
    Laennec's cirrhosis.
    Lancet. 2019;393:131-132.
    PubMed     Text format    


    December 2018
  8. WONG VWS, Adams LA
    Fibroblast growth factor 21 for non-alcoholic steatohepatitis.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)32165.
    PubMed     Text format    


  9. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    PubMed     Text format     Abstract available


  10. SARGENT J, Horton R
    Transforming the landscape of liver disease in the UK.
    Lancet. 2018;392:2332-2333.
    PubMed     Text format    


    November 2018
  11. CARACENI P, Roncadori A, Bernardi M
    Questions in the design of ANSWER - Authors' reply.
    Lancet. 2018;392:1623-1624.
    PubMed     Text format    


  12. ROWE IA, Parker R
    Questions in the design of ANSWER.
    Lancet. 2018;392:1623.
    PubMed     Text format    


    August 2018
  13. MANNS MP, Burra P, Sargent J, Horton R, et al
    The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities.
    Lancet. 2018;392:621-622.
    PubMed     Text format    


    July 2018
  14. BARNETT R
    Liver cirrhosis.
    Lancet. 2018;392:275.
    PubMed     Text format    


    May 2018
  15. GARCIA-TSAO G
    Long-term albumin in cirrhosis: is it the ANSWER?
    Lancet. 2018 May 31. pii: S0140-6736(18)30948.
    PubMed     Text format    


  16. CARACENI P, Riggio O, Angeli P, Alessandria C, et al
    Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
    Lancet. 2018 May 31. pii: S0140-6736(18)30840.
    PubMed     Text format     Abstract available


    March 2018
  17. CHARLTON M
    FGF-19 agonism for NASH: a short study of a long disease.
    Lancet. 2018;391:1124-1126.
    PubMed     Text format    


  18. REIG M, Bruix J
    Lenvatinib: can a non-inferiority trial change clinical practice?
    Lancet. 2018;391:1123-1124.
    PubMed     Text format    


  19. HARRISON SA, Rinella ME, Abdelmalek MF, Trotter JF, et al
    NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2018 Mar 5. pii: S0140-6736(18)30474.
    PubMed     Text format     Abstract available


    February 2018
  20. KUDO M, Finn RS, Qin S, Han KH, et al
    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Lancet. 2018 Feb 9. pii: S0140-6736(18)30207.
    PubMed     Text format     Abstract available


    January 2018
  21. PATTEN DA, Shetty S
    Chronic liver disease: scavenger hunt for novel therapies.
    Lancet. 2018;391:104-105.
    PubMed     Text format    


  22. FORNER A, Reig M, Bruix J
    Hepatocellular carcinoma.
    Lancet. 2018 Jan 4. pii: S0140-6736(18)30010.
    PubMed     Text format     Abstract available


    August 2017
  23. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Text format     Abstract available


    April 2017
  24. WORNS MA, Galle PR
    Immune oncology in hepatocellular carcinoma-hype and hope.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31044.
    PubMed     Text format    


  25. EL-KHOUEIRY AB, Sangro B, Yau T, Crocenzi TS, et al
    Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31046.
    PubMed     Text format     Abstract available


    February 2017
  26. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    PubMed     Text format     Abstract available


    November 2016
  27. KIRBY T
    Profile: The Kirby Institute celebrates 30 years.
    Lancet. 2016;388:2466.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: